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We previously demonstrated that a differentiation inducing drug, vesnarinone induced the growth arrest and p21
waf1 gene
expression in a human salivary gland cancer cell line, TYS. In the present study, we investigated the mechanism of the
induction of p21
waf1 gene by vesnarinone in TYS cells. We constructed several reporter plasmids containing the p21
waf1
promoter, and attempted to identify vesnarinone-responsive elements in the p21
waf1 promoter. By the luciferase reporter
assay, we identiﬁed the minimal vesnarinone-responsive element in the p21
waf1 promoter at 7124 to 761 relative to the
transcription start site. Moreover, we demonstrated by electrophoretic mobility shift assay that Sp1 and Sp3 transcription
factors bound to the vesnarinone-responsive element. Furthermore, we found that vesnarinone induced the histone
hyperacetylation in TYS cells. These results suggest that vesnarinone directly activates p21
waf1 promoter via the activation of
Sp1 and Sp3 transcription factors and the histone hyperacetylation in TYS cells.
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We have previously demonstrated that a differentiation inducing
drug, vesnarinone inhibits the growth of a human salivary gland
cancer cell line, TYS, and induces the expression of p21
waf1,a
potent inhibitor of cyclin dependent kinase (Sato et al, 1997a;
Kawamata et al, 1998). Vesnarinone is currently used as a
chemotherapeutic agent for head and neck cancer combined with
radiation in several countries, such as Japan (Sato et al, 1997b,c),
the United States and India. p21
waf1 is a gene functioning as a cell
cycle blocker, and its expression is usually regulated at transcrip-
tional level. p21
waf1 is known to inhibit cyclin dependent kinase
activity in p53-mediated cell cycle arrest induced by DNA damage
(El-Deiry et al, 1993). Further studies have indicated that p21
waf1 is
also regulated by other transcription factors during cell differentia-
tion and growth arrest (Dulic et al, 1994; Jiang et al, 1994). p21
waf1
promoter contains not only p53-binding sites but also several tran-
scription factor responsive elements (Datto et al, 1995; Nakano et
al, 1997). One of the responsive elements is for a transcription
factor, Sp1. Sp1 responsive elements are located on the upstream
of TATA box of p21
waf1 promoter. It is reported that several extra-
cellular stimuli including butyrate (Nakano et al, 1997),
transforming growth factor-b (Datto et al, 1995), phorbol esters
(Biggs et al, 1996), okadaic acid (Biggs et al, 1996) and retinoic
acid (Liu et al, 1996) activate the transcription of p21
waf1 gene
through the Sp1 responsive elements.
Because TYS cells are reported to have a mutated p53 gene (Sato
et al, 1997a), the expression of p21
waf1 gene and the growth arrest
induced by vesnarinone may be conducted by the p53-independent
pathway in TYS cells. In order to use vesnarinone more effectively
on the patients with several malignancies, including head and neck
cancer, the molecular mechanisms of the growth inhibitory effect
of vesnarinone should be studied. In this experiment, we attempted
to identify the vesnarinone-responsive elements in the p21
waf1
promoter, and clarify the molecular mechanisms of transcriptional
activation of p21
waf1 gene by treatment with vesnarinone in a
human salivary gland cancer cell line, TYS.
MATERIALS AND METHODS
Cell culture and reagents
TYS cells (Yanagawa et al, 1986) were grown in Dulbecco’s modi-
ﬁed Eagle medium (DMEM; Life Technologies, Inc., Gaithersburg,
MD, USA) supplemented with 10% foetal calf serum (FCS; Bio-
Whittaker, Walkersville, MD), 100 mgm l
71 streptomycin,
100 U ml
71 penicillin (Life Technologies, Inc.), and 0.25 mgm l
71
amphotericin B (Life Technologies, Inc.) in a humidiﬁed atmo-
sphere of 95% air and 5% CO2 at 378C. Vesnarinone (Otsuka
Pharmaceutical Company, Tokyo, Japan) was dissolved in dimethyl
sulphoxide (DMSO; Sigma, St. Louis, MO, USA) at a concentra-
tion of 10 mg ml
71 as the ﬁrst stock solution, and the ﬁrst
stock solution was diluted with the complete culture medium
described above. Trichostatin A (TSA; Wako, Osaka, Japan) was
dissolved in ethanol at a concentration of 1 mg ml
71, and diluted
with the complete culture medium at 10 mgm l
71.
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The human wild-type p21
waf1 promoter luciferase fusion plasmid,
WWP-Luc (El-Deiry et al, 1993), was a kind gift from Dr B Vogel-
stein (The Johns Hopkins Oncology Center). The 2.4-kilobase pair
genomic fragment was subcloned into HindIII (Takara Biomedi-
cals, Kusatsu, Japan) site of the luciferase reporter vector, pGL3-
Basic (Promega, Madison, WI, USA) to generate pGL3-WWP
(Kawamata et al, 1999) (Figure 1). pGL3-WWP was digested with
PstI (Takara Biomedicals) and BglII (Takara Biomedicals), and
re-ligated to generate pGL3-WWP-0.2 (Figure 1). pWP124 and
pWPdel-SmaI (Nakano et al, 1997) (Figure 1) were kind gifts from
Dr Toshiyuki Sakai (Kyoto Prefectural University of Medicine).
Transient transfection and luciferase assay
TYS cells (5610
5 cells dish
71) were seeded in 35 mm culture dish
(Falcon; Becton Dickinson Labware, Lincoln Park, NJ, USA) in
DMEM supplemented with 10% FCS. Twenty-four hours later,
the cells were transfected with 5 mg of reporter plasmid DNA by
using Superfect reagent (QIAGEN, Hilden, Germany). Fifteen
hours after transfection, vesnarinone (50 mgm l
71) was added,
and 20 h later, cell lysates were collected. Luciferase activities were
measured by Promega luciferase assay Kit (Promega). The lucifer-
ase activities were normalised by the amount of protein. Each
experiment was repeated at least three times.
Electrophoretic mobility-shift assay
TYS cells (1.5610
6 cells dish
71) were seeded in 100 mm culture
dish (Falcon) in DMEM supplemented with 10% FCS. Twenty-four
hours later, cells were treated with vesnarinone (50 mgm l
71) for
15, 30 and 45 min. Cell lysates were prepared according to the
method described by Chin et al (1996). In brief, cells were lysed
with 50 mM HEPES-KOH (pH 7.9) buffer containing 400 mM
NaCl, 0.2% NP-40, 10% glycerol, 0.1 mM EDTA, 1 mM dithiothrei-
tol (DTT), 1 mM sodium orthovanadate, 0.5 mM phenyl-
methanesulphonyl ﬂuoride (PMSF), 1 mgm l
71 of aprotinin,
1 mgm l
71 of leupeptin, and 1 mgm l
71 of pepstatin A. The
protein concentrations of samples were determined with a Bio-
Rad protein assay kit (Bio-Rad, Hercules, CA, USA). Double
stranded oligonucleotides, (Sp1-A:5 '-GAG GGC GGT CCC GGG
CGG CG-3', and Sp1-B:5 '-GAG GCG GGC CCG GGC GGG
GCG GTT G-3') (Figure 2) were labelled with [g-
32p]ATP (Amer-
sham Pharmacia Biotech., Uppsala, Sweden) by T4 polynucleotide
kinase (Promega), and puriﬁed by a spin column system (Amer-
sham Pharmacia Biotech.). Sp1-A contains two Sp1 sites, and
Sp1-B contains three Sp1 sites (Figure 2). The binding reaction
mixtures consisted of 12 mg of cell lysates and 1 ml of the radiola-
belled probe (approximately 5610
4 c.p.m.) in a binding buffer of
10 mM HEPES-KOH (pH 7.9), 0.1 mM EDTA, 0.01% NP-40,
100 mgm l
71 of poly (dI-dC) (Amersham Pharmacia Biotech.),
and 5% glycerol. The reaction was allowed to proceed for
20 min at room temperature before loading on 6% polyacrylamide
gel at a low-ionic-strength buffer (0.56TBE). The gels were run at
100 V on ice for approximately 1 h and dried. The dried gels were
exposed to X-ray ﬁlm. For supershift experiments, anti-Sp1 and/or
anti-Sp3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) was added to the reaction mixture, and the mixture was
incubated for 20 min at room temperature before addition of the
radiolabelled oligonucleotide.
Histone acetylation in TYS cells by vesnarinone treatment
TYS cells were seeded in 100 mm culture dishes. Twenty-four
hours later, vesnarinone (50 mgm l
71) or TSA (10 mgm l
71) was
added to the medium. Sixteen hours later, the cells were collected
and the nuclear extracts were prepared as follows; cells were
suspended in 400 ml of hypotonic buffer (20 mM HEPES-KOH
(pH 7.9) containing 1 mM EDTA, 1 mM DTT, 20 mM NaF,
1m M sodium orthovanadate, 0.5 mM PMSF, 0.2% NP-40,
1 mgm l
71 leupeptin, 10 units ml
71 aprotinin, and 1 mgm l
71
pepstatin A). Samples were centrifuged at 15000 r.p.m. and the
pellets were resuspended in 200 ml of hypertonic buffer (20 mM
HEPES-KOH (pH 7.9) containing 1 mM EDTA, 1 mM DTT,
20 mM NaF, 1 mM sodium orthovanadate, 0.5 mM PMSF, 0.2%
NP-40, 420 mM NaCl, 20% glycerol, 1 mgm l
71 leupeptin,
10 units ml
71 aprotinin, and 1 mgm l
71 pepstatin A). Samples
were incubated on ice for 20 min and were centrifuged at
15000 r.p.m. for 15 min. The supernatants were used as nuclear
extracts. The protein concentrations of samples were determined
with a Bio-Rad protein assay. Samples were electrophoresed on
SDS-polyacrylamide gel. Proteins from gels were transferred to
nitrocellulose (Bio-Rad) and were detected with an anti-acetylated
Histone H3 antibody (Upstate Biotechnology, Lake Placid, NY,
USA) and an Amersham ECL kit (Amersham Pharmacia Biotech.).
RESULTS
Effect of vesnarinone on the activation of p21
waf1 promoter
Several reporter plasmids (Figure 1) were transiently transfected in
TYS cells, and luciferase activity was examined. Vesnarinone appar-
ently enhanced the luciferase activity from the pGL3-WWP reporter
plasmid in TYS cells when compared with untreated control or
DMSO treatment (Figure 3). Vesnarinone also enhanced the luci-
ferase activity from the pGL3-WWP-0.2 plasmid, which contained
a 215 bp promoter fragment lacking two p53 binding sites (Figure
3). Surprisingly, vesnarinone also enhanced the luciferase activity
from the pWP124 containing only a 124 bp promoter fragment.
However, vesnarinone did not activate a 60 bp promoter fragment
of p21
waf1 in pWPdel-SmaI reporter plasmid (Figure 3).
Electrophoretic mobility-shift assay
According to the results from the luciferase assay, the vesnarinone-
responsive element exists within 77 bp region relative to the TATA
element. This 77 bp region harbours four independent and two
overlapping nearly consensus binding sites for transcription factor
Sp1. They are tentatively termed Sp1-1, Sp1-2, Sp1-3, Sp1-4, Sp1-5
and Sp1-6 from the upstream (Figure 2). To determine if Sp1 or
other proteins can interact with the vesnarinone-responsive
element, electrophoretic mobility-shift assay was performed using
the oligonucleotides containing the Sp1-binding sites. The Sp1-A
contains Sp1-1 and Sp1-2 sites, and the Sp1-B contains Sp1-4,
Sp1-5 and Sp1-6 sites (Figure 2). After treatment with vesnarinone
for 30 min, we detected the shifted band when using the Sp1-A as a
probe (Figure 4A). However, when we used the Sp1-B, we could
not detect any shifted bands after vesnarinone treatment (Figure
4A). As shown in Figure 4B, the mobility shift was detectable at
30 min after treatment with 50 mgm l
71 vesnarinone, and the
intensity of the shifted band increased at 45 min after treatment.
Moreover, this band completely disappeared by adding excess unla-
belled Sp1-A oligonucleotide (data not shown).
Supershift assay
To elucidate whether the retarded bands represent the binding of
Sp1 or Sp3, supershift assay was performed by the nuclear
extracts pre-incubated with anti-Sp1 or anti-Sp3 antibody (Figure
4C). In the presence of anti-Sp1 or anti-Sp3 antibody, the inten-
sity of the shifted band was markedly reduced. The shifted band
completely disappeared in the presence of anti-Sp1 and anti-Sp3
antibody together. When pre-immune rabbit-IgG was added as a
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However, the effect of pre-immune IgG was much weaker than
that of anti-Sp1 or anti-Sp3 antibody. Thus, the effect of pre-
immune IgG was probably due to non-speciﬁc interference of
the IgG protein with the binding of Sp1 or Sp3 protein and
DNA.
Histone acetylation in TYS cells induced by vesnarinone
We investigated whether or not vesnarinone induced histone acet-
ylation in TYS cells. Vesnarinone clearly induced histone
acetylation in TYS cells like as TSA did (Figure 5).
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Figure 1 Plasmid construction. pGL3-WWP is a reporter construct con-
taining 2.3 kb p21
waf1 promoter sequence. pGL3-WWP-0.2, pWP124 and
pWPdel-SmaI are 5'-deletion constructs of the p21
waf1 promoter. pGL3-
WWP-0.2 contains 225 bp of p21
waf1 promoter sequence. pWP124
contains 134 bp and pWPdel-SmaI contains 70 bp of p21
waf1 promoter
sequence.
ctgcagcacgcgaggttccgggaccggctggcctgctggaactcggccaggctcagct
PstI
gctccgcgctgggcagccaggagcctgggccccggggagggcggtcccgggcggcgcg
Sp1-A
Transcription
Start site (0)
Sp1-B (Sp1-1) (Sp1-2)
gtgggccgagcgcgggtcccgcctccttgaggcgggcccgggcggggcggttgtatat
cagggccgcgctgagctgcgccagctgaggtgtgagcagctgccgaagtcag
(sp1-3) (sp1-4) (sp1-5) (sp1-6) TATA
Figure 2 Human p21
waf1 promoter sequence located between
7215 bp and +19 bp. The transcription start site is indicated by the num-
ber 0 on the sequence. Sp1 binding sites tentatively termed Sp1-1, Sp1-2,
Sp1-3, Sp1-4, Sp1-5 and Sp1-6 from the upstream are indicated by under-
lining and shown below the sequence. Sp1-A contains Sp1-1 and Sp1-2
sites, and Sp1-B contains Sp1-4, Sp1-5 and Sp1-6 sites. TATA box is also
indicated by underlining.
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Figure 3 Luciferase assay. TYS cells were seeded in 35 mm dishes in
DMEM supplemented with 10% FCS. Twenty-four hours later, the cells
were transfected in triplicate with 5 mg of the several reporter plasmids
by use of the Superfect reagent. Fifteen hours after transfection, vesnar-
inone (50 mgm l
71) was added, and 20 h later, cell lysates were col-
lected. The luciferase activities of the cell lysates were measured with
a Promega luciferase assay kit. Luciferase activities were normalized by
the amount of protein in cell lysates. Data are shown as means (bars,
s.d.), and are representative of three separate experiments with similar
results.
Sp1-A   +     +     –    –
Sp1-B   –     –     +     +
Ves   –     +     –     +
Sp1-A  +     +     +     +     +     +
Ves  +     –     +     –     +     –
15   15   30   30   45   45 Time
(min)
A
Sp1-A     +      +      +      +       +
Anti-Sp1     –      +      –      –       +
Anti-Sp3     –      –      +      –       +
None-immune IgG     –      –      –      +       –
C
B
Figure 4 Electrophoretic mobility-shift assay (A, B) and supershift assay
(C). Nuclear extracts prepared from vesnarinone (50 mgm l
71)- or
DMSO-treated TYS cells were incubated with a
32P-labelled Sp1-A probe
or Sp1-B probe (A). Nuclear extracts from TYS cells after treatment with
vesnarinone for 15, 30, 45 min and a labelled Sp1-A probe were incubated
in the binding buffer (B). Protein samples were prepared from TYS cells
after treatment with vesnarinone for 45 min. Polyclonal antibody against
Sp1 and/or Sp3 was added to the binding reaction and incubated for
20 min at room temperature before addition of a labelled Sp1-A probe
(C).
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In this study, we examined the molecular mechanisms of the
transcriptional regulation of p21
waf1 gene by a differentiation
inducing drug, vesnarinone. We identiﬁed the minimal vesnari-
none-responsive element in the p21
waf1 promoter at 7124 to
761 relative to the transcription start site, and demonstrated
that vesnarinone enhanced the binding of the transcription
factors Sp1 and Sp3 to the vesnarinone-responsive element.
Furthermore, we found that vesnarinone induced the histone
acetylation in TYS cells.
Sp1 is a ubiquitously expressed nuclear protein that is initially
identiﬁed as a protein that binds and stimulates transcription of
simian virus 40 early promoter (Dynan and Tjian, 1983). Sp1
protein binds to the GC-rich sequences present in a variety of
cellular and viral promoters and stimulates their transcriptional
activity (Lania et al, 1997). Sp3 belongs to the same family of
Sp1 related transcription factor, and it also binds to the GC-rich
sequences (Sp1 binding sites) (Lania et al, 1997). In the p21
waf1
promoter, there are four independent Sp1 binding sites (Sp1-1–
Sp1-4) and two overlapping Sp1 binding sites (Sp1-5, Sp1-6)
(Figure 2). We identiﬁed the Sp1-1 and Sp1-2 site as main vesnar-
inone-responsive elements of the p21
waf1 promoter. Generally,
eukaryotic transcription is regulated by more than one transcrip-
tion factor, and these transcription factors form a complex in
speciﬁc promoter elements via interaction with various cofactors
(Struhl and Moqtaderi, 1998). Sp1 and Sp3 are likely to be tran-
scription factors that have low speciﬁcity to the extra-cellular
stimuli, but they would be indispensable factors in p53-indepen-
dent pathway on the p21
waf1 gene transcriptional activity in our
system.
Vesnarinone induced histone acetylation in TYS cells. Recent
studies demonstrated that there were various kinds of histone acet-
yltransferase (HAT) and histone deacetylase (HDAC) in
mammalian cells, and the level of histone acetylation was
controlled by equilibrium of the activities of HAT and HDAC
(Grunstein, 1997). The transcriptional coactivators, p300 and
CREB binding protein (CBP) are known to possess the HAT activ-
ity, and interact with a wide range of DNA binding proteins,
including Sp1, p53, the RelA (p65) nuclear factor kB subunit,
E2F, MyoD, activator protein 1, several nuclear receptors, and
many others (Yuan et al, 1996; Avantaggiati et al, 1997; Gu and
Roeder, 1997; Lee et al, 1998; Ikeda et al, 2000). Although data
was not shown, we conﬁrmed the expressions of p300, CBP and
HDAC1 proteins in the nucleus of TYS cells.
Several histone acetylation inducing drugs show the growth-
inhibitory effect or differentiation-inducing effect, and are used
as a chemotherapeutic agent on several human malignancies (Chen
et al, 1997; Dion et al, 1997; McCaffrey et al, 1997). The molecular
targets for the differentiation inducing drugs (or histone acetyla-
tion inducing drug) may be different from those for DNA-
damaging drugs. Moreover, activating pathway of the target mole-
cules by differentiation inducing drugs may also be different from
those by DNA-damaging drugs. Thus, the differentiation inducing
drugs, such as vesnarinone may act synergistically on the induction
of p21
waf1 gene with the DNA-damaging therapy, such as radiation
and the administration of conventional chemotherapeutic drugs.
These informations are useful for creating new strategy for differ-
entiation-inducing-therapy.
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